NEW YORK (GenomeWeb News) – With uncertainty over future National Institutes of Health funding and concerns over austerity measures in Europe, investors have recently cooled on the stocks of genomics tools firms.

Following a strong January and modest gains for the remainder of the first quarter, the stocks of genomics tools firms and some molecular diagnostics companies have slumped over the past couple of months, though part of that can be attributed to bearish trends in the broader stock market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.